- call +1-201-465-4211
- email sales@mrinsights.biz
Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.
Scope of the Report:
Herpes Simplex Virus (HSV) is a commonly found human pathogen. Globally, an estimated 4.0 billion people are infected with Herpes Virus. The incidence rate of cold sores, caused by the HSV1 virus, is the second largest worldwide, trailing only behind common cold. About 79% of the US population is infected with HSV1, with about 25-35% of the adults enduring recurrent spate of cold sores. In all, close to 100 million outbreaks of cold sores occur each year in the US.
The classification of drugs for herpes labialis (oral herpes) includes valacyclovir, aciclovir, famciclovir, docosanol and other. The proportion of aciclovir in 2016 is about 17%, and the proportion of valacyclovir is about 45%.
Drugs for herpes labialis (oral herpes) are widely used though external use, oral and injection. The most proportion of drugs for herpes labialis (oral herpes) is oral, and the consumption in 2016 is about 1200 M USD.
North America is the largest consumption place, with a revenue market share nearly 36.5% in 2016. Following North America, Europe is the second largest consumption place with the revenue market share of 28.4%.
Market competition is intense. GSK, Novartis, Teva, Mylan, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The worldwide market for Drugs for Herpes Labialis (Oral Herpes) is expected to grow at a CAGR of roughly 4.9% over the next five years, will reach 2710 million US$ in 2024, from 2040 million US$ in 2019, according to a new study.
This report focuses on the Drugs for Herpes Labialis (Oral Herpes) in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
GSK
Novartis
Teva
Mylan
Cadila
Apotex
Daewoong Pharmaceutical
Livzon
Luoxin
Med shine
Bayer (Campho Phenique)
Blistex
Kelun Group
Hikma
Haiwang
Carmex
Cipher
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Aciclovir
Valacyclovir
Famciclovir
Docosanol
Other
Market Segment by Applications, can be divided into
External Use
Oral
Injection
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Drugs for Herpes Labialis (Oral Herpes) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Drugs for Herpes Labialis (Oral Herpes), with price, sales, revenue and global market share of Drugs for Herpes Labialis (Oral Herpes) in 2017 and 2018.
Chapter 3, the Drugs for Herpes Labialis (Oral Herpes) competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drugs for Herpes Labialis (Oral Herpes) breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Drugs for Herpes Labialis (Oral Herpes) market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Drugs for Herpes Labialis (Oral Herpes) sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Drugs for Herpes Labialis (Oral Herpes) Introduction
1.2 Market Analysis by Type
1.2.1 Aciclovir
1.2.2 Valacyclovir
1.2.3 Famciclovir
1.2.4 Docosanol
1.2.5 Other
1.3 Market Analysis by Applications
1.3.1 External Use
1.3.2 Oral
1.3.3 Injection
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2014-2024)
1.4.1.2 Canada Market States and Outlook (2014-2024)
1.4.1.3 Mexico Market States and Outlook (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2014-2024)
1.4.2.2 France Market States and Outlook (2014-2024)
1.4.2.3 UK Market States and Outlook (2014-2024)
1.4.2.4 Russia Market States and Outlook (2014-2024)
1.4.2.5 Italy Market States and Outlook (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2014-2024)
1.4.3.2 Japan Market States and Outlook (2014-2024)
1.4.3.3 Korea Market States and Outlook (2014-2024)
1.4.3.4 India Market States and Outlook (2014-2024)
1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2014-2024)
1.4.4.2 Egypt Market States and Outlook (2014-2024)
1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
1.4.4.4 South Africa Market States and Outlook (2014-2024)
1.4.4.5 Turkey Market States and Outlook (2014-2024)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 GSK
2.1.1 Business Overview
2.1.2 Drugs for Herpes Labialis (Oral Herpes) Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 GSK Drugs for Herpes Labialis (Oral Herpes) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.2 Novartis
2.2.1 Business Overview
2.2.2 Drugs for Herpes Labialis (Oral Herpes) Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis Drugs for Herpes Labialis (Oral Herpes) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.3 Teva
2.3.1 Business Overview
2.3.2 Drugs for Herpes Labialis (Oral Herpes) Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Teva Drugs for Herpes Labialis (Oral Herpes) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.4 Mylan
2.4.1 Business Overview
2.4.2 Drugs for Herpes Labialis (Oral Herpes) Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Mylan Drugs for Herpes Labialis (Oral Herpes) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.5 Cadila
2.5.1 Business Overview
2.5.2 Drugs for Herpes Labialis (Oral Herpes) Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Cadila Drugs for Herpes Labialis (Oral Herpes) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.6 Apotex
2.6.1 Business Overview
2.6.2 Drugs for Herpes Labialis (Oral Herpes) Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Apotex Drugs for Herpes Labialis (Oral Herpes) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.7 Daewoong Pharmaceutical
2.7.1 Business Overview
2.7.2 Drugs for Herpes Labialis (Oral Herpes) Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.8 Livzon
2.8.1 Business Overview
2.8.2 Drugs for Herpes Labialis (Oral Herpes) Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Livzon Drugs for Herpes Labialis (Oral Herpes) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.9 Luoxin
2.9.1 Business Overview
2.9.2 Drugs for Herpes Labialis (Oral Herpes) Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Luoxin Drugs for Herpes Labialis (Oral Herpes) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.10 Med shine
2.10.1 Business Overview
2.10.2 Drugs for Herpes Labialis (Oral Herpes) Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Med shine Drugs for Herpes Labialis (Oral Herpes) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.11 Bayer (Campho Phenique)
2.11.1 Business Overview
2.11.2 Drugs for Herpes Labialis (Oral Herpes) Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.12 Blistex
2.12.1 Business Overview
2.12.2 Drugs for Herpes Labialis (Oral Herpes) Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Blistex Drugs for Herpes Labialis (Oral Herpes) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.13 Kelun Group
2.13.1 Business Overview
2.13.2 Drugs for Herpes Labialis (Oral Herpes) Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Kelun Group Drugs for Herpes Labialis (Oral Herpes) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.14 Hikma
2.14.1 Business Overview
2.14.2 Drugs for Herpes Labialis (Oral Herpes) Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Hikma Drugs for Herpes Labialis (Oral Herpes) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.15 Haiwang
2.15.1 Business Overview
2.15.2 Drugs for Herpes Labialis (Oral Herpes) Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Haiwang Drugs for Herpes Labialis (Oral Herpes) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.16 Carmex
2.16.1 Business Overview
2.16.2 Drugs for Herpes Labialis (Oral Herpes) Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Carmex Drugs for Herpes Labialis (Oral Herpes) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.17 Cipher
2.17.1 Business Overview
2.17.2 Drugs for Herpes Labialis (Oral Herpes) Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Cipher Drugs for Herpes Labialis (Oral Herpes) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
3 Global Drugs for Herpes Labialis (Oral Herpes) Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)
3.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales and Market Share by Manufacturer (2017-2018)
3.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue and Market Share by Manufacturer (2017-2018)
3.3 Market Concentration Rate
3.3.1 Top 3 Drugs for Herpes Labialis (Oral Herpes) Manufacturer Market Share in 2018
3.3.2 Top 6 Drugs for Herpes Labialis (Oral Herpes) Manufacturer Market Share in 2018
3.4 Market Competition Trend
4 Global Drugs for Herpes Labialis (Oral Herpes) Market Analysis by Regions
4.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales, Revenue and Market Share by Regions
4.1.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales and Market Share by Regions (2014-2019)
4.1.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue and Market Share by Regions (2014-2019)
4.2 North America Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
4.3 Europe Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
4.4 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
4.5 South America Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
4.6 Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
5 North America Drugs for Herpes Labialis (Oral Herpes) by Country
5.1 North America Drugs for Herpes Labialis (Oral Herpes) Sales, Revenue and Market Share by Country
5.1.1 North America Drugs for Herpes Labialis (Oral Herpes) Sales and Market Share by Country (2014-2019)
5.1.2 North America Drugs for Herpes Labialis (Oral Herpes) Revenue and Market Share by Country (2014-2019)
5.2 United States Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
5.3 Canada Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
5.4 Mexico Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
6 Europe Drugs for Herpes Labialis (Oral Herpes) by Country
6.1 Europe Drugs for Herpes Labialis (Oral Herpes) Sales, Revenue and Market Share by Country
6.1.1 Europe Drugs for Herpes Labialis (Oral Herpes) Sales and Market Share by Country (2014-2019)
6.1.2 Europe Drugs for Herpes Labialis (Oral Herpes) Revenue and Market Share by Country (2014-2019)
6.2 Germany Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
6.3 UK Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
6.4 France Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
6.5 Russia Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
6.6 Italy Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
7 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) by Country
7.1 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Sales, Revenue and Market Share by Country
7.1.1 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Sales and Market Share by Country (2014-2019)
7.1.2 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Revenue and Market Share by Country (2014-2019)
7.2 China Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
7.3 Japan Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
7.4 Korea Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
7.5 India Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
7.6 Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
8 South America Drugs for Herpes Labialis (Oral Herpes) by Country
8.1 South America Drugs for Herpes Labialis (Oral Herpes) Sales, Revenue and Market Share by Country
8.1.1 South America Drugs for Herpes Labialis (Oral Herpes) Sales and Market Share by Country (2014-2019)
8.1.2 South America Drugs for Herpes Labialis (Oral Herpes) Revenue and Market Share by Country (2014-2019)
8.2 Brazil Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
8.3 Argentina Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
8.4 Colombia Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
9 Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) by Countries
9.1 Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Sales, Revenue and Market Share by Country
9.1.1 Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Sales and Market Share by Country (2014-2019)
9.1.2 Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Revenue and Market Share by Country (2014-2019)
9.2 Saudi Arabia Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
9.3 Turkey Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
9.4 Egypt Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
9.5 Nigeria Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
9.6 South Africa Drugs for Herpes Labialis (Oral Herpes) Sales and Growth Rate (2014-2019)
10 Global Drugs for Herpes Labialis (Oral Herpes) Market Segment by Type
10.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales, Revenue and Market Share by Type (2014-2019)
10.1.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales and Market Share by Type (2014-2019)
10.1.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue and Market Share by Type (2014-2019)
10.2 Aciclovir Sales Growth and Price
10.2.1 Global Aciclovir Sales Growth (2014-2019)
10.2.2 Global Aciclovir Price (2014-2019)
10.3 Valacyclovir Sales Growth and Price
10.3.1 Global Valacyclovir Sales Growth (2014-2019)
10.3.2 Global Valacyclovir Price (2014-2019)
10.4 Famciclovir Sales Growth and Price
10.4.1 Global Famciclovir Sales Growth (2014-2019)
10.4.2 Global Famciclovir Price (2014-2019)
10.5 Docosanol Sales Growth and Price
10.5.1 Global Docosanol Sales Growth (2014-2019)
10.5.2 Global Docosanol Price (2014-2019)
10.6 Other Sales Growth and Price
10.6.1 Global Other Sales Growth (2014-2019)
10.6.2 Global Other Price (2014-2019)
11 Global Drugs for Herpes Labialis (Oral Herpes) Market Segment by Application
11.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales Market Share by Application (2014-2019)
11.2 External Use Sales Growth (2014-2019)
11.3 Oral Sales Growth (2014-2019)
11.4 Injection Sales Growth (2014-2019)
12 Drugs for Herpes Labialis (Oral Herpes) Market Forecast (2019-2024)
12.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales, Revenue and Growth Rate (2019-2024)
12.2 Drugs for Herpes Labialis (Oral Herpes) Market Forecast by Regions (2019-2024)
12.2.1 North America Drugs for Herpes Labialis (Oral Herpes) Market Forecast (2019-2024)
12.2.2 Europe Drugs for Herpes Labialis (Oral Herpes) Market Forecast (2019-2024)
12.2.3 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Forecast (2019-2024)
12.2.4 South America Drugs for Herpes Labialis (Oral Herpes) Market Forecast (2019-2024)
12.2.5 Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Market Forecast (2019-2024)
12.3 Drugs for Herpes Labialis (Oral Herpes) Market Forecast by Type (2019-2024)
12.3.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales Forecast by Type (2019-2024)
12.3.2 Global Drugs for Herpes Labialis (Oral Herpes) Market Share Forecast by Type (2019-2024)
12.4 Drugs for Herpes Labialis (Oral Herpes) Market Forecast by Application (2019-2024)
12.4.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales Forecast by Application (2019-2024)
12.4.2 Global Drugs for Herpes Labialis (Oral Herpes) Market Share Forecast by Application (2019-2024)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Drugs for Herpes Labialis (Oral Herpes) Picture
Table Product Specifications of Drugs for Herpes Labialis (Oral Herpes)
Figure Global Sales Market Share of Drugs for
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
